MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial
Adding to Previously Reported 68.1% Liver Fat Reduction and Strengthening Its Liver Profile for MetALD Additional Phase 1 Part 3B Data Highlight DA-1726's 1.47 mg/dL Placebo-Adjusted Reduction in Uric Acid After 16 Weeks of Treatment (p<0.001), Despite Normal Mean Uric Acid Levels at...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.